GT Biopharma, Inc. entered into a Securities Purchase Agreement on September 14, 2026, for the private placement of Series M 10% Convertible Preferred Stock and warrants with an aggregate purchase price of $7,450,000. The offering includes up to 8,277.778 shares of preferred stock convertible at $6.10 per share, along with common and vesting warrants exercisable at the same price for five years. Purchasers hold Greenshoe Rights to purchase an additional $30,000,000 in stated value. The preferred stock accrues cumulative dividends at 10% annually until September 2027, increasing to 12% thereafter, payable quarterly. GT Biopharma operates in the biotechnology industry, focusing on developing immunotherapies for cancer treatment.
